BCRX shares have traded in a relatively stable band in recent weeks, with the stock hovering around the mid-$7 range as of mid-November 2026 after touching levels near $8.70 earlier in the period. This measured trading pattern reflects a market that is balancing the company's improving profitability against a pipeline timeline that extends into 2027. Rather than a sharp directional move, the recent price action suggests investors are consolidating positions around a commercial story that continues to strengthen while awaiting the next major clinical data readout. I checked this using Tickeron’s AI Pattern Search Engine to see how the stock’s recent behavior compares to peers.
BioCryst Pharmaceuticals is a global biotechnology company focused on rare diseases, with a particular emphasis on hereditary angioedema. Its commercial foundation is ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein inhibitor approved for prophylaxis against HAE attacks. The oral dosing profile differentiates ORLADEYO from injectable alternatives and underpins the company's competitive position in the HAE market.
Beyond its marketed product, BioCryst is advancing a pipeline of potential first-in-class and best-in-class therapies, including navenibart, an injectable HAE prophylaxis candidate, and BCX17725 for Netherton syndrome, a rare and serious skin condition with no approved treatments. Management has signaled a strategic pivot toward building the pipeline through external innovation, supported by a newly formed scientific advisory board. Investors follow BCRX for both the durability of ORLADEYO's growth and the optionality embedded in its clinical-stage assets.
The most significant recent catalyst was BioCryst's third-quarter 2026 earnings report, released in early November. Total revenue reached $180.3 million, up 13% year over year, while ORLADEYO net revenue grew 20% excluding the divested European business. The quarter included an upper-teens-of-millions contribution from an initial inventory build tied to the transition of ORLADEYO fulfillment to CareMed as the company's specialty pharmacy partner. GAAP net income was $37.9 million, while non-GAAP net income more than doubled to $71.1 million.
Management raised full-year 2026 total revenue guidance to $715 million to $730 million, driven by higher navenibart licensing revenue and international RAPIVAB orders, while keeping ORLADEYO guidance unchanged at $625 million to $645 million. The company also continued its pediatric launch of ORLADEYO pellets, introduced in August for patients aged 2 to 11, and announced approval of a 150 mg pellet formulation for patients 12 and older. Restructuring actions, including the closure of its Birmingham facility, are expected to generate $30 million to $35 million in annualized savings, with cash and equivalents reported at $376 million. From what I see, the cost discipline here is worth watching closely.
Looking ahead, the central question for BCRX is whether commercial momentum and cost discipline can sustain profitability growth into 2027. Investors should monitor the durability of underlying ORLADEYO demand now that the one-time CareMed inventory benefit has worked through, as well as the trajectory of the pediatric launch. On the pipeline front, BCX17725 data for Netherton syndrome is expected before the end of 2026, while pivotal navenibart data through 12 months of therapy remains on track for the third quarter of 2027.
Competitive dynamics in the HAE space, the pace of new patient additions, and the execution of the company's external-innovation strategy will also shape sentiment. While management has signaled confidence in ORLADEYO's resilience against future oral competition, investors should weigh these catalysts alongside broader biotech-sector conditions and the inherent clinical and regulatory risks of drug development. I’m watching this closely as the next data points approach.
In my view, reviewing how automated systems handle stocks like BCRX can add useful perspective to a fundamental analysis. I also checked this using Tickeron’s AI Trend Prediction Engine to gauge broader market signals around the sector. These tools help surface patterns that might otherwise go unnoticed in manual review.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BCRX advanced for three days, in 202 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BCRX as a result. In 73 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for BCRX turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 46 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
The 50-day moving average for BCRX moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
BCRX broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BCRX entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.326) is normal, around the industry mean (6.379). P/E Ratio (-5.696) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (2.097) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. BCRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of small molecule pharmaceuticals
Industry PharmaceuticalsGeneric